Based on pseudovirus and extensive pharmacokinetic data, the company said it believed the 500 mg dose of sotrovimab is sufficient to retain activity against the BA.2 variant, which is in line with all other variants of concern and interest. The monoclonal antibody therapy, sotrovimab, is authorised for emergency use in the United States. The companies are sharing the latest data with global regulatory authorities, Vir said.
